New combo therapy aims to cut blood transfusions in MDS patients
NCT ID NCT04798339
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study tests a combination of two drugs, canakinumab and darbepoetin alfa, in people with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS) who no longer respond to standard treatment. The goal is to see if the combination is safe and can reduce the need for red blood cell transfusions. About 13 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory-Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.